2025
Chapter 48 Multicenter considerations
Passarelli R, Sterling J, Singer E, Kim I. Chapter 48 Multicenter considerations. 2025, 245-248. DOI: 10.1016/b978-0-323-90186-4.00029-8.Peer-Reviewed Original Research
2024
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone
Kim W, Kim K, Kang H, Byun Y, Piao X, Kim Y, Lee S, Yun S, Ha Y, Kim J, Kim I. Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone. Oncology Letters 2024, 29 DOI: 10.3892/ol.2024.14770.Peer-Reviewed Original ResearchMechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC
Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K, Tuiche M, Al-Saadi A, Vyas R, Ganesan S, Gohel S, Coffman F, Parrott J, Quan S, Jha S, Kim I, Schaeffer E, Kothari V, Abdulkadir S, Mitrofanova A. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nature Communications 2024, 15: 352. PMID: 38191557, PMCID: PMC10774320, DOI: 10.1038/s41467-024-44686-5.Peer-Reviewed Original Research
2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazardsThe disparities in clinical trials addressing urologic conditions among lower-income countries
Choksi A, Hayden C, Rahman S, Lokeshwar S, Kim I. The disparities in clinical trials addressing urologic conditions among lower-income countries. Frontiers In Urology 2023, 2: 1069265. DOI: 10.3389/fruro.2022.1069265.Peer-Reviewed Original ResearchClinical trialsUrologic conditionsGlobal burdenHigh-income countriesLower urinary tract symptomsUrinary tract symptomsUrinary tract infectionUrinary bladder neoplasmsBurden of diseaseOncology clinical trialsActive clinical trialsIncome countriesTract symptomsTract infectionsBladder neoplasmsEvidence-based practiceGenitourinary pathologyNational incidenceDisease 2019Prostatic neoplasmsKidney neoplasmsLow-income countriesNeoplasmsTrialsDiseaseProstate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
Kim I. Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT. Investigative And Clinical Urology 2023, 64: 310-311. PMID: 37417555, PMCID: PMC10330420, DOI: 10.4111/icu.20230178.Peer-Reviewed Original Research
2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian followSingle-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve
Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyShort-term outcomesCase seriesRadical prostatectomyAcceptable short-term outcomesSurgeon 2Average prostate weightLearning curveMedian patient ageClavien-Dindo scaleMedian operating timeTotal postoperative complicationsShorter hospital stayLarge case seriesOperating timeProstate-specific antigenRobotic radical prostatectomyInstitutional review boardSignificant learning curveHospital stayMedian followPostoperative complicationsIntraoperative complicationsPerioperative outcomesBlood lossUntargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome
Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome. Analyst 2022, 147: 3043-3054. PMID: 35642979, DOI: 10.1039/d2an00676f.Peer-Reviewed Original ResearchConceptsAtmospheric pressure chemical ionization mass spectrometryPressure chemical ionization mass spectrometryChemical ionization mass spectrometryMass spectrometryLaser diode thermal desorptionIonization mass spectrometryMass/charge ratioMass spectroscopyChemical profilingBackbone fragmentsCharge ratioThermal desorptionSpectrometryMetabolite profilingPeak intensityUrine metabolite profilingUrine samplesSpectroscopyIonsDesorptionHereinUrine metabolitesMultivariate statistical analysisPD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER
Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.Peer-Reviewed Original ResearchSurvival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomesAssociation of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsFactors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct)
Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct). Journal Of The American College Of Surgeons 2021, 233: e230. DOI: 10.1016/j.jamcollsurg.2021.08.622.Peer-Reviewed Original ResearchQuantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations
Chua K, Mikail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. Journal Of The American College Of Surgeons 2021, 233: s310-s311. DOI: 10.1016/j.jamcollsurg.2021.07.643.Peer-Reviewed Original ResearchFactors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC)
Patel H, Sterling J, Srivastava A, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC). Journal Of The American College Of Surgeons 2021, 233: e230-e231. DOI: 10.1016/j.jamcollsurg.2021.08.623.Peer-Reviewed Original ResearchMarginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsQuantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations
Chua K, Mikhail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations. Journal Of Urology 2021, 207: 684-691. PMID: 34694164, DOI: 10.1097/ju.0000000000002258.Peer-Reviewed Original ResearchAbrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.Peer-Reviewed Original ResearchProstate cancer-specific survivalU.S. Preventive Services Task ForceSurvival disparitiesUninsured patientsSocioeconomic quintileProstate cancerInsurance statusMarital statusWorse prostate cancer-specific survivalProstate cancer screening recommendationsCox proportional hazards modelDiagnostic time periodsCancer-specific survivalCancer screening recommendationsProportional hazards modelProstate-specific antigenScreening recommendationsSurvival outcomesInsured patientsWorse outcomesHazards modelPatientsBetter outcomesMedian household incomeUninsured individualsFactors associated with palliative care utilization in advanced and metastatic renal cell carcinoma.
Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 146-146. DOI: 10.1200/jco.2020.39.28_suppl.146.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaRenal cell carcinomaStage IV renal cell carcinomaPalliative care utilizationNational Cancer DatabasePalliative careClinical factorsCare utilizationCell carcinomaStage IIITreatment-specific mannerStage III renal cell carcinomaPC utilizationMetastatic renal cell carcinomaPalliative care useDisease-specific symptomsMultivariable logistic regressionComprehensive cancer programsQuality of lifeOncological guidelinesSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusMultivariable analysis